STOCK TITAN

Voyager Therapeutics corrects Q3 2026 filing header

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K/A

Rhea-AI Filing Summary

Voyager Therapeutics, Inc. reported third-quarter 2026 results; this amendment corrects only the EDGAR submission header to reference Items 2.02 and 9.01, leaving the original disclosures unchanged. Collaboration revenue was $4.014 million, down from $13.365 million in Q3 2025. Net loss narrowed to $24.694 million from $27.892 million in Q3 2025, while total operating expenses were $30.436 million, compared with $43.959 million in Q3 2025. Excluding reimbursed research and development services, non-GAAP net collaboration revenue was $612,000, compared with $11.153 million a year earlier.

Voyager ended September 30, 2026 with $132.133 million in cash, cash equivalents and marketable securities and said its cash runway extends into Q2 2028. The company expects to report PET imaging data from VY7523 in Q4 2026; VY1706 dosing is expected in the next few months, pending enrollment. Its Neurocrine-partnered Friedreich’s ataxia gene therapy program is expected to enter the clinic in the coming months.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • Moderate pointQuarterly net loss narrowed to $24.694 million, from $27.892 million in Q3 2025.

Negative

  • Moderate pointQuarterly collaboration revenue fell to $4.014 million, from $13.365 million in Q3 2025.
Item 2.01 Completion of Acquisition or Disposition of Assets Financial
The company completed a significant acquisition or sale of business assets.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Collaboration revenue $4.014 million Three months ended September 30, 2026; $13.365 million in the comparable 2025 period.
Net loss $24.694 million loss Three months ended September 30, 2026; $27.892 million loss in the comparable 2025 period.
Total operating expenses $30.436 million Three months ended September 30, 2026; $43.959 million in the comparable 2025 period.
Cash, cash equivalents and marketable securities $132.133 million As of September 30, 2026; $201.691 million as of December 31, 2025.
Non-GAAP net collaboration revenue $612,000 Three months ended September 30, 2026; $11.153 million in the comparable 2025 period.
Nine-month collaboration revenue $9.772 million Nine months ended September 30, 2026; $25.038 million in the comparable 2025 period.
Nine-month net loss $77.104 million loss Nine months ended September 30, 2026; $92.295 million loss in the comparable 2025 period.
Cash runway Into Q2 2028 Company-stated cash runway.
net collaboration revenue financial
"non-GAAP net collaboration revenue"
reimbursable research and development services financial
"expenses incurred for reimbursed research and development services"
TRACER™ AAV capsid discovery platform technical
"TRACER™ AAV capsid discovery platform"
multiple ascending dose trial medical
"VY7523 multiple ascending dose trial"
PET imaging data medical
"VY7523 PET imaging data"
cash runway financial
"extended our cash runway into the second quarter of 2028"
Cash runway is the amount of time a company can continue operating using its available cash before needing additional funding or generating enough revenue. It’s like a countdown showing how long a business can keep running with its current funds. Knowing the cash runway helps investors assess the company's financial health and whether it has enough resources to reach its goals or needs to find more support soon.
Collaboration revenue $4.014 million Down from $13.365 million in the comparable 2025 quarter.
Total operating expenses $30.436 million Down from $43.959 million in the comparable 2025 quarter.
Net loss $24.694 million loss Narrowed from $27.892 million in the comparable 2025 quarter.
Cash, cash equivalents and marketable securities $132.133 million As of September 30, 2026; $201.691 million as of December 31, 2025.
Guidance

Voyager expects VY7523 PET imaging data in Q4 2026. VY1706 dosing is expected in the next few months, pending enrollment. The Neurocrine-partnered Friedreich’s ataxia gene therapy program is expected to enter the clinic in the coming months.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were VYGR’s third-quarter 2026 financial results?

Voyager reported $4.014 million of collaboration revenue and a $24.694 million net loss for the third quarter of 2026. The comparable 2025 quarter had $13.365 million of collaboration revenue and a $27.892 million net loss; operating expenses were $30.436 million versus $43.959 million.

How much cash did VYGR report at the end of Q3 2026?

Voyager reported $132.133 million in cash, cash equivalents and marketable securities as of September 30, 2026, and said its cash runway extends into Q2 2028.

How does VYGR define non-GAAP net collaboration revenue?

It excludes reimbursement for research and development services under Neurocrine and Novartis collaboration agreements. Voyager reported $612,000 for the three months ended September 30, 2026, compared with GAAP collaboration revenue of $4.014 million, and said the non-GAAP measure should be considered alongside, not as a substitute for, GAAP results.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
true 0001640266 0001640266 2026-11-05 2026-11-05
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K/A

(Amendment No. 1)

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): November 5, 2026

 

 

Voyager Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-37625   46-3003182

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

75 Hayden Avenue

Lexington, Massachusetts

  02421
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code (857) 259-5340

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.001 par value   VYGR   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


EXPLANATORY NOTE

This Amendment No. 1 to Form 8-K (this “Amendment”) amends Form 8-K of Voyager Therapeutics, Inc. that was originally filed with the Securities and Exchange Commission on November 5, 2026, (the “Original Filing”). This Amendment is being filed solely to correct an inadvertent technical error in the submission of the Original Filing through EDGAR which referenced the incorrect Form 8-K Item Number (Item 2.01) in the EDGAR submission header. This Amendment is being filed through EDGAR to reference the correct Form 8-K Item Numbers (Items 2.02 and 9.01) in the EDGAR submission header. There are no changes to the Original Filing itself (which referenced the correct Item numbers). Except as summarized above, this Amendment continues to speak as of the date of the Original Filing and does not reflect events occurring after the date of the Original Filing or modify or update the disclosures therein in any way.

 

Item 2.02.

Results of Operations and Financial Condition.

On November 5, 2026, Voyager Therapeutics, Inc. (the “Company”) announced third quarter 2026 financial results and corporate updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01.

Financial Statements and Exhibits

(d) Exhibits

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

 

Exhibit
No.

  

Description

99.1    Press release dated November 5, 2026 entitled “Voyager Reports Third Quarter 2026 Financial and Operating Results”.
104    Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 18, 2026   VOYAGER THERAPEUTICS, INC.
    By:  

/s/ Alfred Sandrock

      Alfred Sandrock
     

Chief Executive Officer and Director

(Principal Executive Officer)

 

3

Exhibit 99.1

 

LOGO

Voyager Reports Third Quarter 2026 Financial and Operating Results

- VY7523 clinical data readout on track for Q4 2026 and VY1706 dosing expected in the next few months pending enrollment -

- Neurocrine Biosciences partnered Friedreich’s ataxia gene therapy program expected to enter the clinic in the coming months -

- Ended Q3 2026 with cash position of $132 million, runway into Q2 2028 -

LEXINGTON, Mass., November 5, 2026 — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported third quarter 2026 financial and operating results.

“There is strong momentum behind our two tau-targeted Alzheimer’s disease programs, and we expect to report PET imaging data from our VY7523 multiple ascending dose trial in the fourth quarter and to dose the first patient with our lead gene therapy VY1706 in the next few months,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “During the third quarter, we continued to be disciplined in our operations to reduce year-over-year operating expenses and as a result, we have extended our cash runway into the second quarter of 2028. This strengthens our position as we approach key upcoming milestones.”

Third Quarter 2026 and Recent Business Highlights

 

  •  

VY7523 (anti-tau antibody): The last patient visit is complete, and Voyager continues to expect tau positron emission tomography (PET) imaging efficacy data in Q4 2026 from the multiple ascending dose (MAD) clinical trial in participants with Alzheimer’s disease (AD).

 

  •  

VY1706 (tau silencing gene therapy): Patient screening continues in the United States for the clinical trial in adults with early AD, and, pending enrollment, Voyager expects patient dosing to begin in the next few months, initial acute safety data in the first quarter of 2027, and the potential to establish capsid platform validation with initial CSF tau biomarker-based data approximately one year after dosing begins.

 

  •  

Presentation at ESGCT 2026: Voyager presented a pharmacology and safety summary from its 6-month good laboratory practice (GLP) toxicology non-human primate (NHP) study of VY1706.

 

  •  

NBIB-‘223 (Friedreich’s ataxia gene therapy): Voyager’s partner, Neurocrine Biosciences, said that the program is expected to enter a Phase 1 clinical study in the coming months, with initial patient-level data anticipated in 2027.

 

  •  

Robin Swartz appointed as President: As announced in October 2026, as part of a planned leadership transition, Swartz was appointed President and is expected to succeed current CEO Dr. Sandrock.

Upcoming Presentations

 

  •  

Guggenheim 3rd Annual Healthcare Innovation Conference, November 9, 2026: fireside chat and participating in one-on-ones.


  •  

Stifel 2026 Healthcare Conference, November 10, 2026: fireside chat at 2:00 p.m. ET and participating in one-on-ones. A webcast of the fireside chat will be available and may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com. A replay will be archived on Voyager’s website for at least 30 days.

 

  •  

19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, November 16-19, 2026: poster presentations summarizing the baseline characteristics of patients enrolled in the VY7523 MAD clinical study and the design of the first-in-human study for VY1706.

 

  •  

Antibody Engineering & Therapeutics US 2026 Conference, December 13-16, 2026: poster presentation on the Voyager NeuroShuttle™ platform including identification and characterization of ALPL antibodies and in vivo PK in mice and non-human primates.

Third Quarter 2026 Financial Results

 

  •  

Collaboration Revenues: Collaboration revenue was $4.0 million for the third quarter of 2026, compared to $13.4 million for the third quarter of 2025. The decrease was primarily attributable to lower revenue recognized under the Neurocrine collaboration agreement as activities transition beyond the research phase.

 

  •  

Research and Development Expenses: Research and development expenses were $24.4 million for the third quarter of 2026, compared to $35.9 million for the third quarter of 2025. The decrease was primarily attributable to lower clinical and manufacturing costs and program prioritization.

 

  •  

General and Administrative Expenses: General and administrative expenses were $6.1 million for the third quarter of 2026, compared to $8.1 million for the third quarter of 2025. The decrease was primarily attributable to lower employee-related expenses and consulting costs.

 

  •  

Net Loss: Net loss was $24.7 million for the third quarter of 2026, compared to $27.9 million for the third quarter of 2025.

 

  •  

Cash and Cash Equivalents and Marketable Securities: Cash, cash equivalents, and marketable securities as of September 30, 2026, were $132.1 million. Based on Voyager’s current operating plans, the company expects its cash, cash equivalents, and marketable securities, together with anticipated collaboration reimbursements and interest income, to be sufficient to fund planned operating expenses and capital expenditures into the second quarter of 2028.

About Voyager Therapeutics

Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit http://www.voyagertherapeutics.com.

Voyager Therapeutics® is a registered trademark, and TRACER™ and Voyager NeuroShuttle™ are trademarks, of Voyager Therapeutics, Inc.


Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws about Voyager’s belief, expectations, plans and prospects regarding the development, regulatory status of its product candidates and advancement of its preclinical and clinical development programs, including Voyager’s advancement of the tau silencing gene therapy program in AD, VY1706, and the expected timing of enrollment, dosing and initial acute safety data, and initial biomarker-based data; the progress and timing of Voyager’s clinical-stage anti-tau antibody program in AD, VY7523, including the timing of expected clinical tau PET imaging efficacy data and other clinical data; Voyager’s ability to advance gene therapy product candidates under the Novartis licenses and collaboration and Neurocrine collaboration, including the anticipated progression into the clinic by Neurocrine for NBIB-‘223 in FA; the role of tau in the treatment of AD, including as a critical disease-modifying target; the therapeutic potential, safety, and pharmacological effect of Voyager’s current and future product candidates; Voyager’s anticipated financial results, including the anticipated receipt by Voyager of revenues or reimbursement payments from collaboration partners; Voyager’s cash runway, anticipated cost savings, including as a result of cost-cutting and efficiency initiatives, and its ability to execute across its pipeline and platforms; the mission, goals and value drivers for Voyager’s business; Voyager’s expected succession plan; Voyager’s anticipated presentation at upcoming events and conferences; and the ability to generate sufficient cash resources to enable Voyager to continue its business and operations through multiple clinical inflection points. The use of words such as “may,” “will,” “might,” “would,” “could,” “should,” “expect,” “plan,” “anticipate,” “believe,” “view,” “potential,” “intend,” “seek,” “predict,” “estimate,” “project,” “target,” or “continue” and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

All forward-looking statements are based on management’s current estimates and assumptions and are subject to a number of risks, uncertainties and important factors that may cause actual results to differ materially from any forward-looking statements in this press release. Factors include, among others, the risks and uncertainties inherent in the development of product candidates, including the timing, initiation, and conduct of preclinical studies and clinical trials, including potential delays in timing as a result of slower than expected site initiation, slower than expected enrollment, the need or decision to expand the trials, conduct additional pre-clinical studies, or other changes, which may impact Voyager’s ability to meet its expected timelines and may increase its costs; the expectations and decisions of regulatory authorities; the availability of data from and outcomes of Voyager’s preclinical studies and clinical trials and those conducted by its partners and collaborators, including that success in earlier preclinical studies may not be repeated or observed in ongoing or future preclinical studies or clinical trials, ongoing and future clinical trials may not meet their primary or key secondary endpoints, which may substantially impair development, timing for expected data may be delayed, and Voyager may encounter adverse events that could negatively impact further development; Voyager’s ability to demonstrate that current or future product candidates are safe and effective for their proposed indications; the availability, commercial potential and success of Voyager’s wholly owned candidates; the availability of data from and the outcomes of third-party preclinical studies and clinical trials and the potential impact on Voyager’s development plans; the continued development of Voyager’s technology platforms, including Voyager’s TRACER and nonviral discovery platforms; Voyager’s scientific approach and program development progress and the restricted supply and increased costs of critical research components; the development by third parties of capsid identification platforms that may be competitive to Voyager’s TRACER capsid and nonviral discovery platform and programs; Voyager’s ability to create and protect intellectual property rights associated with the TRACER capsid and nonviral discovery platforms, the capsids and ligands identified by the platforms, and the development of clinical candidates and related data from Voyager’s pipeline programs; the willingness and ability of Voyager’s


collaboration partners to meet obligations under collaboration agreements with Voyager and their projections with respect to such programs; the need to align with its collaborators, which may hamper or delay its development efforts and timelines; the possibility or timing of Voyager’s receipt of program reimbursement, development or commercialization milestone payments, option exercise, and other payments under Voyager’s existing licensing or collaboration agreements; the success of programs controlled by third-party collaboration partners in which Voyager retains a financial interest, including that the anticipated benefits of these ongoing collaborations, including the receipt of payments or the successful development or commercialization of products and generation of revenue, may never be achieved at the levels or timing Voyager expects or at all; the adverse impact on Voyager’s business if any of its key collaborators fails to perform its obligations or terminates the collaboration; the ability of Voyager to negotiate and complete licensing or collaboration agreements with other parties on terms acceptable to Voyager and the third parties; additional funding may not be available on acceptable terms when needed, or at all, which could hamper Voyager’s development efforts; the ability to attract and retain talented directors, employees, and contractors and the resulting impact to Voyager’s business and ability to meet its goals and timelines; the sufficiency of Voyager’s cash resources to fund its operations and pursue its corporate objectives; any of the foregoing events could impair the drivers and value creation opportunities for Voyager’s business; and technical and other unexpected hurdles in the development, manufacture and supply of product candidates, may delay Voyager’s timing, change its plans, increase its costs, or otherwise negatively impact its business.

These risks and uncertainties are described in Voyager’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as updated by its subsequent filings with the Securities and Exchange Commission. All information in the press release is as of the date of this press release, and any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Contacts

Company and Investors: Andrea Zuniga, investors@vygr.com

Media: Lisa Guiterman, voyagerpr@scientpr.com


Consolidated Balance Sheet

(in thousands)

(Unaudited)

 

     September 30,
2026
     December 31,
2025
 

Assets

     

Cash, cash equivalents and marketable securities

   $ 132,133      $ 201,691  

Accounts receivable, including related party collaboration receivable

     4,274        1,912  

Property and equipment, net

     9,767        13,136  

Operating lease right-of-use assets

     24,579        28,478  

Other assets

     6,300        7,064  
  

 

 

    

 

 

 

Total assets

   $ 177,053      $ 252,281  
  

 

 

    

 

 

 

Liabilities and stockholders’ equity

     

Deferred revenue

   $ —       $ 1,590  

Operating lease liabilities

     30,507        36,499  

Other liabilities

     11,435        18,111  
  

 

 

    

 

 

 

Total liabilities

     41,942        56,200  

Total stockholders’ equity

     135,111        196,081  
  

 

 

    

 

 

 

Total liabilities and stockholders’ equity

   $ 177,053      $ 252,281  
  

 

 

    

 

 

 

Consolidated Statement of Operations

(in thousands, except per share data)

(Unaudited)

 

     Three Months Ended     Nine Months Ended  
     September 30,     September 30,  
     2026     2025     2026     2025  

Collaboration revenue

   $ 4,014     $ 13,365     $ 9,772     $ 25,038  

Operating expenses:

        

Research and development

     24,371       35,866       71,014       98,722  

General and administrative

     6,065       8,093       21,842       28,228  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     30,436       43,959       92,856       126,950  
  

 

 

   

 

 

   

 

 

   

 

 

 

Operating loss

     (26,422 )      (30,594 )      (83,084 )      (101,912 ) 

Total other income

     1,746       2,785       6,032       9,752  
  

 

 

   

 

 

   

 

 

   

 

 

 

Loss before income taxes

     (24,676 )      (27,809 )      (77,052 )      (92,160 ) 

Income tax provision

     18       83       52       135  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss

   $ (24,694 )    $ (27,892 )    $ (77,104 )    $ (92,295 ) 
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss per share, basic and diluted

   $ (0.40 )    $ (0.47 )    $ (1.27 )    $ (1.57 ) 
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted-average common shares outstanding, basic and diluted

     61,824,703       58,803,015       60,631,494       58,608,075  
  

 

 

   

 

 

   

 

 

   

 

 

 


GAAP vs. Non-GAAP Financial Measures

Voyager’s financial statements are prepared in accordance with generally accepted accounting principles in the United States, or GAAP, and represent revenue and expenses as reported to the Securities and Exchange Commission. Voyager has provided in this release certain financial information that has not been prepared in accordance with GAAP, including net collaboration revenue and net research and development expenses, which exclude the impact of reimbursement by Neurocrine Biosciences (Neurocrine) and Novartis Pharma AG (Novartis) for expenses we incur in conducting preclinical development activities under our collaboration agreements. Management uses these non-GAAP measures to evaluate the Company’s operating performance in a manner that allows for meaningful period-to-period comparison and analysis of trends in its business. Management believes that such non-GAAP measures are important in comparing current results with prior period results and are useful to investors and financial analysts in assessing the Company’s operating performance. Non-GAAP financial measures are not required to be uniformly applied, are not audited and should not be considered in isolation. The non-GAAP measures give investors and financial analysts a better understanding of our net revenue and net research and development expenses without the pass-through impact of Neurocrine costs. The non-GAAP financial information presented here should be considered in conjunction with, and not as a substitute for, the financial information presented in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures set forth below.

Reconciliation of GAAP to Non-GAAP Measures

(in thousands)

 

     Three Months Ended      Nine Months Ended  
     September 30,      September 30,  
     2026      2025      2026      2025  

GAAP collaboration revenue

   $ 4,014      $ 13,365      $ 9,772      $ 25,038  

Revenue recognized for reimbursed research and development services (Note 1)

     3,402        2,212        7,815        6,229  
  

 

 

    

 

 

    

 

 

    

 

 

 

Net collaboration revenue

   $ 612      $ 11,153      $ 1,957      $ 18,809  
  

 

 

    

 

 

    

 

 

    

 

 

 

GAAP total research and development expenses

   $ 24,371      $ 35,866      $ 71,014      $ 98,722  

Expenses incurred for reimbursed research and development services (Note 1)

     3,402        2,212        7,815        6,229  
  

 

 

    

 

 

    

 

 

    

 

 

 

Net research and development expenses

   $ 20,969      $ 33,654      $ 63,199      $ 92,493  
  

 

 

    

 

 

    

 

 

    

 

 

 

Note 1: Under the Company’s existing collaboration agreements with Neurocrine and Novartis, Neurocrine and Novartis have agreed to be responsible for all costs the Company incurs in conducting preclinical development activities for certain collaboration programs, in accordance with joint steering committee agreed upon workplans and budgets. Reimbursable research and development services performed during the period are captured within collaboration revenue and research and development expenses in the Company’s consolidated statements of operations. During the three and nine months ended September 30, 2026, the Company incurred $3.4 million and $7.8 million of reimbursable research and development services recorded within collaboration revenue and research and development expenses, respectively. During the three and nine months ended September 30, 2025, the Company incurred $2.2 million and $6.2 million of reimbursable research and development services recorded within collaboration revenue and research and development expenses, respectively.

Filing Exhibits & Attachments

4 documents

Keep reading